 Polycythemia Vera
"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C15.378.190.636.753
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 2 | 1 | 3 | | 2009 | 0 | 2 | 2 | | 2013 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Zhao Y, Sotolongo G, Deak K, Wang E. Acute myeloid leukemia arising from polycythemia vera underwent reversion to chronic phase of myeloproliferative neoplasm status post chemotherapy: Biclonal myeloid neoplasms with genomic evidence of a common early hematopoietic progenitor. Hematol Oncol. 2021 Apr; 39(2):254-257.
-
Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 Jan; 176(1):76-85.
-
Hou JL, Onajin O, Gangat N, Davis MD, Wolanskyj AP. Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2017 03; 58(3):715-717.
-
Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL. A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations. J Mol Diagn. 2013 Sep; 15(5):592-9.
-
Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95.
-
Odenike O. Beyond JAK inhibitor therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2013; 2013:545-52.
-
Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
-
Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009 Sep 01; 115(17):3842-7.
-
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15; 110(4):1092-7.
-
Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007 Aug 01; 110(3):986-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|